Home›Lansoprazole›Lansoprazole + Mycophenolate Mofetil

Does Lansoprazole Interact with Mycophenolate Mofetil?

CDI records a moderate classification for Lansoprazole and Mycophenolate Mofetil. The stored summary is: Examples Lansoprazole, pantoprazole Drugs that Interfere with Enterohepatic Recirculation Clinical Impact Concomitant use with drugs that directly interfere with enterohepatic recirculation, or indirectly interfere with enterohepatic recirculation by altering the gastrointestinal flora, can decrease MPA systemic exposure [see Clinical Pharmacology ( 12.3 )] , which may reduce mycophenolate mofetil efficacy Prevention or Management Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Evidence status

A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.

Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.

Stored CDI classification: Moderate
Lansoprazole Class: Proton Pump Inhibitor
Management: Confirm exact products with your pharmacist
Data Source: U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Lansoprazole and your doctor is considering prescribing Mycophenolate Mofetil (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Ask whether any dosage adjustments are needed
Never stop or change either medication without first consulting your healthcare provider

💊 Lansoprazole(Prevacid)+💊 Mycophenolate Mofetil(Cellcept)

Severity & Interaction Details

🟡

moderate

Stored CDI classification: moderate

A current source comparison has not been recorded for this claim. The stored classification does not determine the clinical significance for your exact products or circumstances.

Severity scale

MinorContra

On record

Yes

Drug A class

Proton Pump Inhibitor

Drug B class

—

Source

FDA drug label - mycophenolate mofetil

What this means in plain English

Examples Lansoprazole, pantoprazole Drugs that Interfere with Enterohepatic Recirculation Clinical Impact Concomitant use with drugs that directly interfere with enterohepatic recirculation, or indirectly interfere with enterohepatic recirculation by altering the gastrointestinal flora, can decrease MPA systemic exposure [see Clinical Pharmacology ( 12.3 )] , which may reduce mycophenolate mofetil efficacy Prevention or Management Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil.

About Lansoprazole and Mycophenolate Mofetil

Lansoprazole is a Proton Pump Inhibitor. You may recognize them by the brand names Prevacid and Cellcept. Mycophenolate Mofetil additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: FDA drug label - mycophenolate mofetil

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

PubMed

Paraprobiotics Derived From Bifidobacterium animalis Subsp. LactisBB-12 Attenuates Indomethacin-Induced Gastric Ulcer by Inhibiting the PANoptosis Pathway.about Lansoprazole · 2026-10

PubMed

Tragopogon coelesyriacus Boiss. attenuates ethanol-induced gastric ulcer in vivo: modulation of oxidative stress, inflammation, and apoptosis.about Lansoprazole · 2026-09

PubMed

Repurposing of lansoprazole and nitazoxanide as NR2F2 inhibitors in the gastric cancer cell line GCIY: computational insights and siRNA-mediated in vitro tests.about Lansoprazole · 2026-08

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Lansoprazole and Mycophenolate Mofetil against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.